The chairman's open-market purchase at $1.40/share provides a floor of confidence ahead of the Phase 3 NCP trial initiation. Monitor for trial enrollment updates and potential partnership or financing announcements given the $46M market cap and upcoming clinical catalyst.
Price Chart
Executive Summary
OKYO Pharma's Chairman Gabriele Cerrone purchased 25,000 ordinary shares at $1.40/share through Panetta Partners Ltd, increasing his total holdings to 10,851,416 shares (20.51% of issued share capital). This insider open-market buy signals alignment with shareholders ahead of a planned Phase 3 pivotal trial for urcosimod in neuropathic corneal pain (NCP). The purchase is modest in absolute dollar terms ($35,000) but represents a meaningful vote of confidence from the largest shareholder at a $46M market cap.
Key Facts
- Chairman Gabriele Cerrone purchased 25,000 ordinary shares at $1.40 per share
- Cerrone's total holdings increased to 10,851,416 shares, representing 20.51% of issued share capital
- Purchase made through Panetta Partners Ltd, an entity in which Cerrone has a beneficial interest
- OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of 2026 for urcosimod in NCP
Financial Impact
$35,000 purchase (25,000 shares × $1.40)
Risk Factors
- Clinical-stage biotech with no approved products; Phase 3 trial may fail or be delayed
- Small purchase size ($35K) relative to market cap limits signaling power
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-033991 |
| Exhibit: ex99-1.htm | 0001493152-26-033991 |
| Document: 0001493152-26-033991-index-headers.html | 0001493152-26-033991 |
| Document: 0001493152-26-033991-index.html | 0001493152-26-033991 |
| Document: 0001493152-26-033991.txt | 0001493152-26-033991 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 6-K | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.44 (−1.37%) |
Oct 6, 2026 20d ago | Press Release | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.44 (−1.37%) |
Sep 29, 2026 27d ago | 6-K | $1.36 $1.29 | ▼ −5.15% | ▼ −4.94% | $1.44 (+5.88%) |
Sep 8, 2026 6w ago | 6-K | $1.53 $1.45 | ▼ −5.23% | ▼ −4.76% | $1.44 (−5.88%) |
Aug 7, 2026 11w ago | Insider Cluster | $1.57 $1.52 | ▼ −3.18% | ▼ −2.87% | $1.44 (−8.28%) |
Jul 28, 2026 12w ago | 6-K | $1.64 $1.64 | · 0.00% | ▲ +1.54% | $1.44 (−12.20%) |
Jul 27, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▼ −0.24% | $1.44 (−12.20%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.44 (−2.70%) |
Jul 23, 2026 13w ago | Press Release | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.44 (−2.70%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.44 (−2.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers